-
Optimizing Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Harboring PI3K/AKT/PTEN Pathway Abnormalities
- 2024/11/19
- 再生時間: 57 分
- ポッドキャスト
-
サマリー
あらすじ・解説
Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Hope S Rugo from the UCSF Helen Diller Family Comprehensive Cancer Center discuss treatment decision-making for HR-positive metastatic breast cancer in patients who harbor PI3K/AKT/PTEN pathway mutations.